PureTech Health (GB:PRTC) has released an update.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
PureTech Health has announced promising results for its experimental drug LYT-200, designed to treat relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). The drug, which targets the galectin-9 protein, shows potential both as a standalone treatment and in combination with existing therapies, achieving disease stabilization or better in a majority of patients. These findings suggest LYT-200 could become a significant new option for AML patients, bolstering PureTech’s position in the biotherapeutics market.
For further insights into GB:PRTC stock, check out TipRanks’ Stock Analysis page.
